Xvivo Perfusion Insider Purchases Yet To Pay Off Regardless Of Recent Strength

Insiders who bought kr2.17m worth of Xvivo Perfusion AB (publ) (STO:XVIVO) stock in the last year have seen some of their losses recouped as the stock gained 11% last week. However, the purchase is proving to be a costly gamble, since losses made by insiders have totalled kr648k since the time of purchase.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Xvivo Perfusion Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by the Chief Executive Officer, Christoffer Rosenblad, for kr960k worth of shares, at about kr457 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (kr180). So it is hard to draw any strong conclusion from it. The only individual insider seller over the last year was Christoffer Rosenblad.

Over the last year, we can see that insiders have bought 8.45k shares worth kr2.2m. On the other hand they divested 4.10k shares, for kr1.9m. In total, Xvivo Perfusion insiders bought more than they sold over the last year. Their average price was about kr256. I'd consider this a positive as it suggests insiders see value at around the current price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

See our latest analysis for Xvivo Perfusion

Xvivo Perfusion is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Xvivo Perfusion Insiders Bought Stock Recently

It's good to see that Xvivo Perfusion insiders have made notable investments in the company's shares. Not only was there no selling that we can see, but they collectively bought kr627k worth of shares. This could be interpreted as suggesting a positive outlook.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. From looking at our data, insiders own kr25m worth of Xvivo Perfusion stock, about 0.4% of the company. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. I generally like to see higher levels of ownership.

So What Do The Xvivo Perfusion Insider Transactions Indicate?

The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. When combined with notable insider ownership, these factors suggest Xvivo Perfusion insiders are well aligned, and that they may think the share price is too low. Of course, the future is what matters most. So if you are interested in Xvivo Perfusion, you should check out this free report on analyst forecasts for the company.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.